Teiko.bio

The Technology

We read millions of cells using mass cytometry

Mass Cytometry is a technology used to determine specific properties of cells.

It is an advanced cytometry method that builds upon the established science of flow cytometry while eliminating many of the common challenges associated with the technique.

Armed with in-depth immune information, researchers can make informed decisions around patient response and drive new pathway discoveries.

High-resolution analysis of specific immune markers can provide insight into patient response

High-resolution analysis of specific immune markers can provide insight into patient response

Learn More

Mass vs. Flow Cytometry

Mass Cytometry is a technology used to determine specific properties of cells.

It is an advanced cytometry method that builds upon the established science of flow cytometry while eliminating many of the common challenges associated with the technique.

Armed with in-depth immune information, researchers can make informed decisions around patient response and drive new pathway discoveries.

Flow Cytometry

Flow Cytometry

  • 10-15 markers per assay
  • Significant signal overlap due to fluorescence
  • Extensive time to optimization
  • Multiple sample consumption for result
MASS Cytometry

MASS Cytometry

  • Up to 45 unique markers per assay
  • High-resolution, minimal signature overlap
  • Reduced time to optimization
  • Single sample consumption for result
Page Anchor: #human-panel – Not Visible On Front

Expertly Designed Human Pan-Immune Panel

The TokuProfile Human Pan-Immune panel includes:

  • Markers to identify every major immune cell population and subsets
  • Expression of key co-stimulatory and co-inhibitory molecules that regulate cell function
  • Markers of recent activation and effector function
  • Up to 10 open channels for customization included
Customize your human panel

  • T cells

    CD3
    Total T cells
    CD4
    CD4+ T cells
    CD8a
    CD8+ T cells
    CD27
    Maturation
    CD45RA
    Naive/Memory
    CCR7 (CD197)
    Naive/Memory
    Foxp3
    Treg
    CD25
    Treg, activation
    CD127
    T cell subsets
    T-bet
    T cell subsets
    CD38
    Maturation
    HLA-DR
    Activation
    TCF1
    Stemness
    CD7
    T cell subsets
    CD56
    NKT, T cell subsets
    gdTCR
    gdT cells
    CTLA-4 (CD152)
    Checkpoint
    PD-1
    Checkpoint
    TIM-3
    Checkpoint
    TIGIT
    Checkpoint
    LAG3
    Checkpoint

  • B cells

    CD19
    Total B cells
    CD25
    Activation
    CD27
    Naive/Memory
    CD38
    Naive/Memory
    HLA-DR
    Antigen presentation

  • NK cells

    CD56
    NK cell subsets
    CD16
    NK cell subsets
    CD8a
    NK cell subsets
    CD7
    NK cell subsets
    CD38
    Activation
    T-bet
    Maturation

  • Myeloid cells

    CD11b
    Monocytes, macrophages
    CD11c
    Monocytes, macrophages, DCs
    CD14
    Monocyte subsets, Macrophages
    CD16
    Monocyte subsets
    CD33
    Total myeloid
    CD123
    pDC
    PD-L1
    Checkpoint ligand
    HLA-DR
    Antigen presentation

  • Granulocytes

    Whole blood only
    CD11b
    Neutrophils
    CD16
    Neutrophils
    CD123
    Basophils

  • General

    CD45
    Total immune cells
    KI67
    Proliferation
    CD61
    Platelets
    CD235ab
    Erythrocytes
    CD66b
    Granulocytes
    DNA
    Singlets
    Live/Dead
    Viability

  • 10 open channels for customization

Turning Data into Insights

Single cells in the data are classified based on their protein expression profiles.

Abundances of different immune cell subsets are quantified.

Activation states of each immune cell subset are quantified.

A regularized regression model is trained on these ~500 features to build a classifier of response.

Page Anchor: #technical-whitepaper-panel-and-custom-antibody-validation-process – Not Visible On Front
Technical Whitepaper

Technical Whitepaper

Teiko Bio’s Panel and Custom Antibody Validation Process

Fill out the form below to download the full technical whitepaper.